Objective: To determine if progressive brain atrophy could be detected over
1- and 2-year intervals in relapsing MS, based on annual MR studies from t
he Multiple Sclerosis Collaborative Research Group (MSCRG) trial of interfe
ron beta-1a (Avonex). Methods: All subjects had mild to moderate disability
, with baseline expanded disability status scores ranging from 1.0 to 3.5,
and at least two relapses in the 3 years before study entry. Atrophy measur
es included third and lateral ventricle width, brain width, and corpus call
osum area. Results: Significant increases were detected in third ventricle
width at year 2 and lateral ventricle width at 1 and 2 years. Significant d
ecreases in corpus callosum area and brain width were also observed at 1 an
d 2 years. Multiple regression analyses suggested that the number of gadoli
nium-enhancing lesions at baseline was the single significant contributor t
o change in third ventricle width. Atrophy over 1 and 2 years as indicated
by enlargement of the third and lateral ventricle and shrinkage of the corp
us callosum was greater for patients entering the trial with enhancing lesi
ons. Greater disability increments over 1 and 2 years were associated with
more severe third ventricle enlargement. Conclusion: In patients with relap
sing MS and only mild to moderate disability, significant cerebral atrophy
is already developing that can be measured over periods of only 1 to 2 year
s. The course of cerebral atrophy in MS appears to be influenced by prior i
nflammatory disease activity as indicated by the presence of enhancing lesi
ons. Brain atrophy measures are important markers of MS disease progression
because they likely reflect destructive and irreversible pathologic proces
ses.